Top Banner
1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004
47

1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

Dec 21, 2015

Download

Documents

Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

1

Advertising when experts choose and insurers pay:

Selling drugs to patients

Rhema VaithianathanUniversity of Auckland

CAER Workshop28 January 2004

Page 2: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

2

The Issue

• NZ and US permit Direct-to-consumer advertising (DTC) advertising of prescription drugs

• Prescription drugs is a doctor’s decision, so why is advertising to patients profitable?

Page 3: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

3

Economic Explanations for Advertising (Bagwell, 2001)

• Persuasive

• Search goods

• Signaling quality of experience goods

• Entry-deterrence

• Complement to consumption

• All work at the purchaser level

Page 4: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

4

The general intuition of present paper

• When goods are purchased by uninformed consumers consulting an expert in a signaling game, advertising can change the equilibrium of the doctor-patient game

Page 5: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

5

• Example of advertising for a BMI of 35– “Xenical may be right for you if you are

considerably overweight (at least 30% above ideal weight or a BMI of 30 or greater) …or you have other risk factors such as high blood pressure, high cholesterol, heart disease or diabetes.”

Page 6: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

6

Drug company’s view

“As managed care becomes the health care model and cost containment the watchword, physicians are no longer the magic road to profits. ...The physician in managed care is being dictated [to about] what he prescribes. The idea in going to the patient is to get the patient to pull the product through.” (US Drug Marketing Executive)

Page 7: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

7

Patient’s View

• “one patient informed me that it was her body and that drug companies used DTC because Doctors don’t have patient’s best interest at heart’!! (NZ GP Survey)

Page 8: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

8

Doctor’s View

“I have lost quite a few patients because I did not prescribe Xenical, Reductil, Symbicort etc. (advertised drugs) because they were not appropriate” (NZ GP survey)

Page 9: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

9

The Policy Context

Page 10: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

10

DTC and physician promotion trends (US)

0

2,000

4,000

6,000

8,000

10,000

12,000

14,000

1996 1997 1998 1999 2000

Physician Promotion

DTC

Source: Rosenthal, Berdnt and Donohue et al (2003)

Page 11: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

11

Banning DTCA favoured

• DTCA is thought to

1. Increases utilisation and expenditure

2. Uninformative due to the drug company bias

3. Interferes with patient-doctor relationship

4. Inappropriate prescribing

Page 12: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

12

Objective

• Analyse incentives on the part of the advertiser to advertise prescription drugs

• Compare three regimes:

1. DTCA Banned

2. Permissive DTCA

3. Regulated DTCA

Page 13: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

13

The Model

Page 14: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

14

Timing of Game

DTCA BANNED Nature moves - Doctor signals state to

patient Patient forms belief on

state and {REQUEST, NOT REQUEST}

Doctor {TREAT, NOT TREAT}

DTCA

1. Nature moves

2. Advertiser {AD, No AD}

3. Doctor signals state to patient

4. Patient forms belief on state and {REQUEST, NOT REQUEST}

5. Doctor {TREAT, NOT TREAT}

Page 15: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

15

1. State of Nature () determines net benefit to patient

e.g. patient has BMI of 35, is Xenical a good idea? 4 states with equal probability

2. Drug company observes state and advertises or not

eg: “Xenical is proven effective for those with BMI >30”

– Permissive Regime• Advertise permitted in all states

– Truth-in-Advertising Regime• Advertise only allowed in states where benefits are greater

than side-effects

Page 16: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

16

3 – 5. Patient doctor game• All patients see the doctor• Doctor signals state

• e.g. “The side effects of Xenical greater than benefit for patients with BMI < 40”

• Patient observes advertising and what the doctor says• Patient decides on REQUEST

• “I want to be prescribed Xenical”

• Doctor decides on TREAT

Page 17: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

17

Payoff

• Doctor cares about benefit to patient BUT supply side cost sharing scheme imposes c every time he prescribes

• If a patient requests and doctor refuses, there is conflict cost of d and p

• 69% of NZ GPs surveyed said they felt under pressure to prescribe advertised drug (Toop, 2003)

• Costs for drug co to advertise

• Gets when drug prescribed

Page 18: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

18

Payoffs

Doctor Patient Drug Company

Advertise Not Advertise

No Request 0 0 - 0

Request and Treat

benefit () – c

benefit ()

Request and Not Treat

d p -

Page 19: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

19

State HState R State r State h

d “conflict cost”

Patient Patient

Patient

Patient

Treatment Pay-offs ( )

-R

-r

h

H

-R-c

-r-c

h-c

H-c

DoctorDoctor

Doctor

Doctor

Page 20: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

20

d

Patient Patient

Patient

Patient

Incentives ( )

-R

-r

h

H

-R-c

-r-c

h-c

H-c

DoctorDoctor

Doctor

Doctor

Doctor NO REQUEST NO REQUEST NO REQUEST REQUEST

…if requested

REFUSE TREAT TREAT TREAT

Patient NO REQUEST NO REQUEST REQUEST REQUEST

Page 21: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

21

Equilibrium

Page 22: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

22

Solution concept

• DTCA Banned is a 2 player cheap-talk game• DTCA permitted is a 3 player signaling game• Pure Strategy • Perfect Bayesian Nash Equilibrium

– on observing AD/ NO AD and hearing doctor, patients update on state using Bayes rule (where possible)

– Everyone’s message/ actions maximise their expected utility

• Neologism proof

Page 23: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

23

DTCA Banned Game

1. Nature moves

2. -

3. Doctor signals state to patient

4. Patient forms belief on state and {REQUEST, NOT REQUEST}

5. Doctor {TREAT, NOT TREAT}

Page 24: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

24

An Equilibrium in DTCA Banned Game

H’ h’ r’ R’If Doctor Says:

Patient Believes:

H {h,r,R} {h,r,R} {h,r,R}

H h r R

Doctor Says H R R R

Patient REQUEST ? ? ?

Doctor TREATS

Page 25: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

25

What does the patient do if she believes {h,r,R}?

• Bayes rule and pure strategy implies equal chance of h,r, and R

• NOT REQUEST if h-r-d<0

• We refer to this as {H} REQ {h,r,R}NREQ

Page 26: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

26

{H} REQ {h,r,R}NREQ

H’ h’ r’ R’If Doctor Says:

Patient Believes:

H {h,r,R} {h,r,R} {h,r,R}

H h r R

Doctor Says H R R R

Patient REQUEST NOT REQUEST

NOT REQUEST

NOT REQUEST

Doctor TREATS

Page 27: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

27

The Neologism Proof Refinement

• Due to Farrell (1993)

• Credible off equilibrium statements can break equilibria

• It is therefore a refinement of PBNE

• Allows us to eliminate the following equilibria

Page 28: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

28

{H,h,r,R}NREQ is PBNEAssume H+h-r-p < 0

H’ h’ r’ R’If Doctor Says:

Patient Believes:

{H,h,r,R}

H h r R

Doctor Says R R R R

Patient NOT REQUEST

NOT REQUEST

NOT REQUEST

NOT REQUEST

{H,h,r,R} {H,h,r,R} {H,h,r,R}

Page 29: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

29

DTCA Banned Equilibria

• Equilibria depends on size of h • The smaller the h the better the agency

relationship

r+p < h {H,h,r,R}REQ Doctor-patient conflict

r+p>h {H}REQ {h,r,R}REQ Patient Compliance

Page 30: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

30

Permissive DTCA

Page 31: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

31

Drug Company

• Can advertise in any state

• Does not want to advertise in R

• Patients know this

Page 32: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

32

{H}REQ { h,r}REQ {R}NREQ is NP-PBNEAssume h > r

H’ h’ r’ R’If Doctor Says:

Patient Believes:

{h,r} if AD

R if no AD

H h r R

Drug Co NO AD AD AD NO AD

Doctor Says H’ (Ad or not) R’ (Ad or not) R’ (Ad or not) R’ (Ad or not)

Patient REQUEST REQUEST REQUEST NOT REQUEST

{H}{h,r} if AD

R if no AD

{h,r} if AD

R if no AD

Page 33: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

33

Advertising with Permissive DTCA

• The DTCA Banned NO AD equilibria continue to be equilibria • Additional Advertising Equilibria are

r < h {H}REQ,NO AD { h,r}REQ,AD {R}NREQ,

Advertising is Informative

r>h No Advertising Equilibria

Doctor is too good an agent

Page 34: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

34

Truth-in-Advertising

Page 35: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

35

Drug Company

• Can advertise only in H and h

• Patients know this

• So, when observing advertising, always believe {H,h}

• Advertising is as credible as the doctor

• Advertising equilibria always exists

Page 36: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

36

{H}REQ { h}REQ {r,R}NREQ is NP-PBNE

H’ h’ r’ R’If Doctor Says:

Patient Believes:

{h} if AD

R if no AD

H h r R

Drug Co NO AD AD (NO AD) (NO AD)

Doctor Says H’ (Ad or not) R’ (Ad or not) R’ R’

Patient REQUEST REQUEST REQUEST NOT REQUEST

{H} if H’,

AD or not

{h} if AD

R if no AD

{h} if AD

R if no AD

Page 37: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

37

Advertising with Regulated DTCA

• {H}REQ,No AD { h}REQ,AD {r,R}NREQ is always an equilibria

• When h is small, NO ADVERTISING is no an equilibria under regulated regime

Page 38: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

38

Summary

Page 39: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

39

Banned Permissive Regulated

h > r + p

“Conflict”

{H,h,r,R}REQ No-Ad plus

{H}REQ,NOAD

{h,r}REQ,AD

{R}NREQ,NO AD

No-Ad plus

{H}REQ,NOAD

{h}REQ,AD

{R}NREQ,NO AD

h< r + p

“Partial Agency”

{H}REQ {h,r,R}NREQ

No Ad plus

{H}REQ,NOAD

{h,r}REQ,AD

{R}NREQ,NO AD

{H}REQ,NOAD

{h}REQ,AD

{R}NREQ,NO AD

h < r

“Strong Agency”

H}REQ {h,r,R}NREQ

NO EQ {H}REQ,NOAD

{h}REQ,AD

{R}NREQ,NO AD

Increasing Agency

Page 40: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

40

Arguments against DTCA

Page 41: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

41

“DTCA increases utilisation and the drug bill ”

• Maximum states are 3

• Care with interpreting empirical studies

• Equilibrium advertising is followed by REQUEST and TREAT

• Does not imply that advertising induces treatment

Number of States in which the drug is sold

Banned Permissive Advertising

Regulated

h > r + p

“Conflict”

3 3 2

h< r + p

“Partial Agency”

1 3 2

h < r

“Strong Agency”

1 NO EQ 2

Page 42: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

42

“DTCA increases doctor-patient conflict”

• Advertising reduces conflict costs (d)

• US vs. NZ

Doctor’s pay-off

Patient’s Pay-off

Banned Permissive Advertising

Regulated

h > r + p

“Conflict”

H + h –r -3c -d

H + h –r - d

H + h –r -3c

H + h –r

H + h –2c

H+h

h< r + p

“Partial Agency”

H-c

H

H + h –r -3c

H + h - r

H + h –2c

H + h

h < r

“Strong Agency”

H-c

H

No Equilibrium

H + h –2c

H + h

Page 43: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

43

“Drug companies never comply with regulated DTCA”

• Drug companies maximise their profit with banning and doctor agent conflict

• Prefer regulation under strong agency

Drug Company Pay-off

Banned Permissive Advertising

Regulated

h > r + p

“Conflict”

3 3 2

h< r + p

“Partial Agency”

3 2

h < r

“Strong Agency”

No Equilibrium

2

Page 44: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

44

“DTCA increases harmful treatment”

Drug prescribed is state r?

Advertising in state r?

Banned Permissive Advertising

Regulated

h > r + p

“Conflict”

Yes

No Ad

Yes

Ad

No

No

h< r + p

“Partial Agency”

No

No Ad

Yes

Ad

No

No

h < r

“Strong Agency”

No

No Ad

No Equilibrium

No

No

• Drug never prescribed or advertised in R

• Regulated advertising minimises harmful treatment

• Drug companies never advertise in H

Page 45: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

45

Industry View Supports Regulation

• [regulation of DTCA] builds public confidence in advertising, and thereby increases the effectiveness of advertising investments, by acting in visible ways to ensure the accuracy of the information consumers get in ads.'' (Advertising Age, 2003)

Page 46: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

46

Conclusion

• advertising only works when there is some doctor-patient conflict

• patients always (ex post) better off with advertising

• Drug companies, doctors and third-party payers may or may not be better off with banning

• Regulation needs to monitor r states not R

Page 47: 1 Advertising when experts choose and insurers pay: Selling drugs to patients Rhema Vaithianathan University of Auckland CAER Workshop 28 January 2004.

47

Additional Issues

• Equilibrium Selection

• Ignore strategic pricing of drugs

• Ex-ante efficiency

• Supply side cost sharing (h) is endogenous

• Doctors might have superior information